Skip to content
PeptideAgent

Clinics in Kentucky

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Kentucky law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Kentucky at a glance

Pharmacy regulator
Kentucky Board of Pharmacy
503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Kentucky

No verified clinics serving Kentucky are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Kentucky

Yes, but Kentucky's Board of Pharmacy has been unusually explicit about GLP-1 copies. A Kentucky resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Kentucky-licensed provider, including by telehealth, since KRS 211.336 lets a practitioner-patient relationship begin via telehealth. Compounded peptides are available only when eligible under federal 503A rules and dispensed by a Kentucky-permitted pharmacy; Kentucky Board of Pharmacy regulation 201 KAR 2:076 separately prohibits compounding essential copies of commercially available drugs, and the Board's 2025 guidance states that pharmacies in general may not compound semaglutide or tirzepatide. [1] [2] [3] [4] [5] [6] [7] [9] [10] [15]

Compounded GLP-1 access in Kentucky

The Kentucky Board of Pharmacy's 2025 guidance, "Important Update: Compounding Semaglutide and Tirzepatide," states that in general compounding pharmacies may not compound semaglutide or tirzepatide because they are commercially available, that adding another ingredient such as B12 does not avoid the essentially-a-copy rule, that a lower price is not a valid reason, and that noncompliant compounding may lead to action by both FDA and the Board. The narrow exceptions are a documented patient-specific change that produces a significant difference for that patient, or a return of the drug to the FDA shortage list. [3] [4] [13]

Research use only sellers in Kentucky

Only Kentucky-permitted pharmacies may dispense prescription drugs to Kentucky patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and fall outside Kentucky's compounding regulation. The Kentucky Food, Drug and Cosmetic Act, KRS 217.075, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has become effective under the federal act; its investigational exemption covers only drugs intended solely for investigational use by qualified experts and labeled for investigational use only. [1] [8] [14]

Kentucky notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth. The Kentucky Board of Pharmacy's 2025 guidance says compounding pharmacies in general may not compound semaglutide, and 201 KAR 2:076 makes the essentially-a-copy prohibition enforceable by the Board; adding B12 does not change that. [3] [4]
  • Tirzepatide: Available branded by prescription. The same Kentucky guidance covers tirzepatide: 503A compounding under the shortage allowance ended in 2025, and compounded copies are allowed only for a documented significant patient-specific difference. [3] [13]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. Because it is not commercially available, the essentially-a-copy rule does not apply to it; Kentucky pharmacies apply the federal bulks eligibility test. [4] [11] [12]

How to check a clinic in Kentucky

  1. Confirm the prescribing clinician's license with the Kentucky medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Kentucky Board of Pharmacy license lookup. [1] [3] [4] [7] [10]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Kentucky. [1] [8] [14]

Common questions in Kentucky

Do I need an in-person visit to get a prescription by telehealth in Kentucky?

Not necessarily. KRS 211.336 allows a practitioner-patient relationship to begin via telehealth, and an in-person meeting is required only if the provider decides it is medically necessary. The prescriber must be licensed in Kentucky. [5] [6]

All peptide legal questions for Kentucky

Sources

  1. [1]Kentucky Board of Pharmacy
  2. [2]Kentucky Board of Medical Licensure
  3. [3]Kentucky Board of Pharmacy: Important update, compounding semaglutide and tirzepatide (2025)2025
  4. [4]201 KAR 2:076, Compounding (Kentucky Board of Pharmacy)
  5. [5]KRS 211.336, Telehealth practitioner-patient relationship
  6. [6]KRS 311.5975, Duty of treating physician utilizing telehealth
  7. [7]KRS 315.0351, Out-of-state pharmacy permit (Kentucky Legislative Research Commission)
  8. [8]KRS 217.075, Restrictions on handling of new drugs (Kentucky Food, Drug and Cosmetic Act)
  9. [9]201 KAR chapter 9, Kentucky Board of Medical Licensure regulations (Legislative Research Commission index)
  10. [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA